Levothyroxine group ("sham discontinuation") for Hypothyroidism

"Given that Levothyroxine group ("sham discontinuation") has received approval from the FDA, our team at Power rated its safety a 3 out of possible 3."

"Levothyroxine group ("sham discontinuation") is a common therapeutic intervention for treating malignant neoplasms, euthyroid goitre, obesity, and hypothyroidism."

"The clinical trial under discussion is not presently seeking participants. It was initially posted on March 2nd 2021, and its last edit occurred on June 22nd 2022. If you are looking for alternative studies, there are presently 13 trials searching for patients with hypothyroidism and 10 more trials actively recruiting members of the Levothyroxine group (“sham discontinuation”)."

"This research program necessitates that prospective participants are aged between 18 and 89, with a distinct 5 studies for minors and 20 for seniors."

"This trial is not currently enrolling and the listing was last edited on June 22nd, 2022. If you are looking for alternative trials related to hypothyroidism or Levothyroxine group ("sham discontinuation"), there are 13 and 10 active studies respectively which may be of interest."

"This medical trial's principal aim is to measure completion rates over a 6-month period from the start of recruitment. Additional objectives include an evaluation of participants' tiredness and hypothyroid symptoms scores compared with baseline values at 6 weeks, as well as changes in lipid levels after 6 months; negative differences for former two parameters reflect worse outcomes whereas positive discrepancies signify poorer results for the latter."

"This medical trial seeks to recruit 50 participants with hypothyroidism, aged between 18 and 89. Most notably, potential candidates must have been a Veteran diagnosed with SCH in the time period of January 1st 2009 and December 31st 2019 at Central Arkansas Veterans Healthcare System (CAVHS)."